FMC — FMC Corporation

FMC Corporation Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales: $762 million, exceeding guidance by $12 million but down 4% year-over-year; up 1% on a like-for-like basis excluding India.
• EBITDA: $72 million, $17 million above the high end of guidance.
• Adjusted EPS: Loss of $0.23, better than guidance by $0.15.
• Free Cash Flow: Negative $628 million, slightly worse than the prior year.
• Debt: Gross debt increased to approximately $4.5 billion; net debt rose to about $4.1 billion, reflecting normal seasonal working capital build.

2. Strategic Updates and Business Highlights

• FMC is targeting a $1 billion debt reduction in 2026, with significant progress on the sale of its India commercial business and potential licensing agreements for new active ingredients.
• The company is optimizing its manufacturing cost structure by shifting production to lower-cost plants in Asia, expected to be completed by Q1 2027.
• New active ingredients, including Isoflex and fluindapyr, showed strong growth, with sales doubling year-over-year in Q1.
• Regulatory approval for Isoflex in the EU was achieved, marking a significant milestone for future sales.

3. Forward Guidance and Outlook

• Q2 Revenue Guidance: Expected between $850 million and $900 million, reflecting a 17% decline at the midpoint primarily due to lower sales to diamide partners and the removal of India.
• Full Year 2026 Guidance: Sales projected at $3.6 billion to $3.8 billion (down 5% at midpoint), EBITDA of $670 million to $730 million (17% decline), and adjusted EPS of $1.63 to $1.89 (41% decline).
• The second half of 2026 is expected to show improved results, driven by volume growth particularly in Latin America and new active ingredients.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Increased competition from low-cost generics, particularly affecting sales in Latin America and Asia.
• Pricing Declines: Average prices down 6%, with significant reductions in partner sales impacting overall revenue.
• Interest Expense: Increased interest expense due to higher rates on subordinated debt and short-term borrowing costs, expected to rise to $255 million to $275 million for the full year.
• Input Cost Uncertainty: Potential impact from rising energy and raw material costs due to geopolitical tensions, particularly the conflict in Iran.

5. Notable Q&A Insights

• Sales Organization Impact: The new sales organization is expected to drive increased orders in Brazil for the second half, with significant orders already in hand.
• Rynaxypyr Strategy: The company is seeing early signs of success in gaining market share from other insecticides, particularly in North America, but faces challenges from generics as the year progresses.
• Licensing Opportunities: FMC is in advanced negotiations for licensing one of its new active ingredients, with potential for upfront payments.
• Tariff Refunds: Ongoing discussions regarding tariff refunds, with some categories showing a higher probability of recovery than others.

Overall, while FMC has made progress in several strategic areas, it faces significant challenges from competitive pressures, pricing declines, and rising costs, which will require careful management moving forward.